From Wikipedia, the free encyclopedia
Beclamide
Clinical data
Routes of
administration
By mouth
ATC code
Legal status
Legal status
Identifiers
  • N-Benzyl-3-chloropropanamide
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard ( EPA)
ECHA InfoCard 100.007.207 Edit this at Wikidata
Chemical and physical data
FormulaC10H12ClNO
Molar mass197.66 g·mol−1
3D model ( JSmol)
Melting point94 °C (201 °F)
  • ClCCC(=O)NCc1ccccc1
  • InChI=1S/C10H12ClNO/c11-7-6-10(13)12-8-9-4-2-1-3-5-9/h1-5H,6-8H2,(H,12,13) checkY
  • Key:JPYQFYIEOUVJDU-UHFFFAOYSA-N checkY
   (verify)

Beclamide (marketed as Chloracon, Hibicon, Posedrine, Nydrane, Seclar, and other names) is a drug that possesses anticonvulsant activity. [2] It is no longer used.

Uses

It has been used as a sedative and as an anticonvulsant.

It was studied in the 1950s for its anticonvulsant properties, as a treatment for generalised tonic-clonic seizures. It was not effective for absence seizures.

Interest in the drug resumed in the 1990s for its psychiatric properties as an adjunct in the treatment of schizophrenia. [3]

Side effects

Side effects are uncommon but include stomach pain, nervousness, giddiness, skin rash and leukopenia. It is counter-indicated in breast feeding as it is passed in the milk.

Administration and pharmacology

Administration is oral, though it has an unpleasant taste. It is quickly absorbed and elimination is renal and complete within 48 hours. Beclamide is possibly metabolized to 3-chloropropanoic acid in vivo,[ citation needed] which binds to the GHB receptor.

References

  1. ^ Anvisa (2023-03-31). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 2023-04-04). Archived from the original on 2023-08-03. Retrieved 2023-08-16.
  2. ^ Ahmadi M, Nicholls PJ, Smith HJ, Spencer PS, Preet-Ryatt MS, Spragg BP (October 1995). "Metabolism of beclamide after a single oral dose in man: quantitative studies". The Journal of Pharmacy and Pharmacology. 47 (10): 876–8. doi: 10.1111/j.2042-7158.1995.tb05757.x. PMID  8583359. S2CID  19556266.
  3. ^ Raptis C, Garcia-Borreguero D, Weber MM, Dose M, Bremer D, Emrich HM (February 1990). "Anticonvulsants as adjuncts for the neuroleptic treatment of schizophrenic psychoses: a clinical study with beclamide". Acta Psychiatrica Scandinavica. 81 (2): 162–7. doi: 10.1111/j.1600-0447.1990.tb06472.x. PMID  2183543. S2CID  26772370.
  • The Medical Treatment of Epilepsy by Stanley R Resor. Published by Marcel Dekker (1991). ISBN  0-8247-8549-5.